Day & Ennis’s Edwards Lifesciences EW Stock Holding History

Day & Ennis’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-207	Closed	-$8K	–	83
2017 Q2	$8K	Buy	+207	New	+$7.56K	0.01%	92

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Day & Ennis's EW Position: Q3 2017 in Review

Day & Ennis sold out of Edwards Lifesciences (EW) in Q3 2017, closing a stake of 207 shares — an estimated $8K sold.

Day & Ennis first reported a position in EW in Q2 2017 and held it in 1 quarter. The position peaked at $8K in Q2 2017. 740 funds tracked by Wall St. Rank hold EW as of Q3 2017.

Day & Ennis reported no remaining Edwards Lifesciences position as of Q3 2017 after selling out during the quarter.
Day & Ennis sold 207 Edwards Lifesciences shares in Q3 2017, an estimated $8K.
Day & Ennis first reported a position in Edwards Lifesciences in Q2 2017 and held it in 1 quarter.
Day & Ennis's Edwards Lifesciences position peaked at $8K in Q2 2017.
740 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2017.

Based on Day & Ennis's 13F filing for Q3 2017, filed 13 Nov 2017.